Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient

Anesthesiology. 2007 Aug;107(2):350-3. doi: 10.1097/01.anes.0000271866.37280.85.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anesthesia, General / adverse effects*
  • Anesthesia, General / methods
  • Anesthetics, Inhalation / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure / drug effects
  • Colostomy
  • Creatine Kinase / blood*
  • Dantrolene / therapeutic use
  • Gastroesophageal Reflux / complications
  • Genetic Predisposition to Disease
  • Heart Rate / drug effects
  • Heterozygote*
  • Humans
  • Hypertension / complications
  • Isoflurane / adverse effects
  • Male
  • Malignant Hyperthermia / diagnosis
  • Malignant Hyperthermia / drug therapy
  • Malignant Hyperthermia / genetics*
  • Metoprolol / therapeutic use
  • Monitoring, Intraoperative / methods
  • Muscle Relaxants, Central / therapeutic use
  • Osteoarthritis / complications
  • Pulmonary Embolism / complications
  • Rectal Neoplasms / complications
  • Rectal Neoplasms / surgery*
  • Ryanodine Receptor Calcium Release Channel / genetics*
  • Time Factors
  • Venous Thrombosis / complications

Substances

  • Anesthetics, Inhalation
  • Antihypertensive Agents
  • Muscle Relaxants, Central
  • Ryanodine Receptor Calcium Release Channel
  • Isoflurane
  • Creatine Kinase
  • Dantrolene
  • Metoprolol